DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bacterial Genomic Sequencing in Overactive Bladder

Information source: Loyola University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Overactive Bladder

Intervention: Solifenacin (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Loyola University

Official(s) and/or principal investigator(s):
Alan J Wolffe, PhD, Principal Investigator, Affiliation: Loyola University Chicago

Summary

No one really knows what causes overactive bladder syndrome (OAB). Urinary tract infection (UTI)causes similar symptoms to OAB with the difference being the presence of bacteria, as evidenced by routine microbiology cultures. Recent work by the group on the genitourinary microbiome (GUM) has shown that female urine, even in the absence of culture evidence of bacteria does have evidence of bacterial DNA. Bacterial 16S rRNA can be isolated from urine and sequenced to identify bacterial species present in urine. From this the investigators can hypothesize that urinary bacteria contribute to urinary symptoms and that there is a difference in the bacterial communities in the urine of women who respond to Solifenacin, a drug used to treat OAB, versus those that do not.

Clinical Details

Official title: The Effect of Short Term Solifenacin for Overactive Bladder on the Female Urinary Microbiome

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Bacterial Genomic Sequencing

Detailed description: This is a prospective cohort study with 2 groups: Women who have accepted a clinical recommendation for OAB treatment with solifenacin and a comparator (control) group of women unaffected by OAB. All women will have a baseline urine assessment with bacterial genome sequencing. Solifenacin treated patients will also have urine assessments with bacterial genomic sequencing at 4 and 12 weeks on treatment.

Eligibility

Minimum age: 18 Years. Maximum age: 89 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Controls: Women without bother from urinary symptoms will be screened for potential

study participation using the pelvic floor distress inventory (PFDI). Women with negative urinary responses will be further screened for participation using the following eligibility criteria:

- no anticholinergic medications for bladder conditions,

- no antibiotic exposure in the past 4 weeks for any reason,

- no immunologic deficiency,

- no pelvic malignancy or pelvic radiation, and

- Untreated symptomatic POP > POP-Q Stage II.

OAB cohort: Women with bother from overactive bladder symptoms will be screened for potential study participation using the pelvic floor distress inventory (PFDI). Women with positive urinary responses for urge predominant symptoms will be further screened for participation using the following eligibility criteria:

- willing to take Solifenacin as treatment for OAB,

- no neurological disease known to affect the lower urinary tract,

- no current UTI (based on urine dipstick) or recurrent UTI,

- no antibiotic exposure in the past 4 weeks for any reason,

- no immunologic deficiency,

- no pelvic malignancy or pelvic radiation,

- untreated symptomatic POP > POP-Q Stage II,

- no contraindications to receiving Solifenacin.

Exclusion Criteria:

- Women who are of child-bearing potential who are pregnant, nursing, intending to

become pregnant during the study or not practicing a reliable form of contraception are also excluded.

Locations and Contacts

Loyola University Chicago Health Sciences Division, Maywood, Illinois 60153, United States
Additional Information

Starting date: July 2012
Last updated: September 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017